登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
ClinicalTrials.gov 上登记的一项肺癌开放试验,由山东第一医科大学第一附属医院(山东省千佛山医院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06883136,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
60 岁 至 80 岁;性别:不限
登记记录的入选字段
Study participants with histologically or cytologically confirmed locally advanced (IIIB-IIIC) or metastatic (stage IV) NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer 8th Edition TNM stage), inoperable and definitive concurrent chemoradiotherapy without previous systemic therapy;
入选标准第 3 条
No EGFR gene sensitive mutation or ALK gene fusion mutation was confirmed by histological specimens; At least one radiographic measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
入选标准第 4 条
Euthyroid, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH level was outside the normal range, participants were eligible if their total T3 (or FT3) and FT4 levels were within the normal range.
入选标准第 15 条
unstable angina, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure;
排除标准第 16 条
Had not received any previous systemic antitumor therapy for advanced/metastatic disease. Participants who had received previous platinum-based adjuvant/neoadjuvant chemotherapy or definitive chemoradiotherapy for advanced disease were allowed if they had disease progression or relapse at least 6 months after the last dose of chemotherapy.
入选标准第 5 条
Are currently participating in an interventional clinical study treatment, or have received another study drug or study device within 4 weeks before the first dose;
排除标准第 2 条
Prior therapy with: Anti-pd-1, anti-PD-L1 agents or agents targeting another T-cell receptor that stimulates or coinhibits it (e.g., CTLA-4, OX-40, CD137) Such as tislelizumab, toripalimab, carrelizumab, atezolizumab, slulizumab, pembrolizumab, paiampalimab, nivolumab, duvalumab, ipilimumab, etc.
排除标准第 3 条
Received systemic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control pleural effusion) with indications for anti-NSCLC within 2 weeks before the first dose;
排除标准第 4 条
absolute neutrophil count (ANC) ≥1.5x109/L without using granulocyte colony-stimulating factor for the past 14 days;
入选标准第 8 条
platelet count ≥100×109/L without blood transfusion in the past 14 days;
入选标准第 9 条
hemoglobin >9g/dL in the absence of blood transfusion or erythropoietin use in the past 14 days;
入选标准第 10 条
Total bilirubin ≤1.5 times upper limit of normal value (ULN)
入选标准第 11 条
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 ×ULN (participants with liver metastases were allowed ALT or AST ≤5×ULN);
入选标准第 12 条
serum creatinine ≤1.5 times ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min;
入选标准第 13 条
Malignant diseases other than NSCLC diagnosed within 5 years before the first dose (excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, and/or radical resection in situ carcinoma);
排除标准第 1 条
Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive);
排除标准第 10 条
Untreated active hepatitis B (defined as both HBsAg positivity and HBV-DNA copies greater than the upper limit of normal in the laboratory at the participating center);
排除标准第 11 条
HBV viral load <1000 copies /ml (200 IU/ml) before the first dose, study participants should receive anti-HBV therapy throughout the study chemotherapy to avoid viral reactivation
排除标准第 12 条
Study participants with anti-HBc (+), HBsAg (-), anti-hbs (-), and HBV viral load (-) do not require prophylactic anti-HBV therapy, but close monitoring for viral reactivation is required 12. Active HCV-infected study participants with positive HCV antibodies and HCV-RNA levels above the lower limit of detection; 13. A live vaccine dose within 30 days before the first dose (cycle 1, day 1); Note: Administration of injectable inactivated virus vaccine against seasonal influenza within 30 days before the first dose is allowed; Live, attenuated, intranasal influenza vaccine was not allowed.
排除标准第 13 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06883136,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Provided written informed consent before performing any trial-related procedures; Age 60-80 years old; Study participants with histologically or cytologically confirmed locally advanced (IIIB-IIIC) or metastatic (stage IV) NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer 8th Edition TNM stage), inoperable and definitive concurrent chemoradiotherapy without previous systemic therapy; No EGFR gene sensitive mutation or ALK gene fusion mutation was confirmed by histological specimens; At least one radiographic measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Had not received any previous systemic antitumor therapy for advanced/metastatic disease. Participants who had received previous platinum-based adjuvant/neoadjuvant chemotherapy or definitive chemoradiotherapy for advanced disease were allowed if they had disease progression or relapse at least 6 months after the last dose of chemotherapy. Study participants with asymptomatic or symptomatic stable brain metastases after local treatment were allowed to enroll as long as the study participant met the following conditions: measurable lesions outside the central nervous system 2) no central nervous system symptoms or worsening of symptoms for at least 2 weeks 3) no glucocorticoid treatment was required, glucocorticoid treatment was discontinued within 7 days before the first dose, or the glucocorticoid dose was stable and reduced to less than 10mg/ day prednisone (or equivalent) within 7 days before the first dose 8. Study participants were allowed to receive palliative radiation therapy 7 days before the first dose of study drug and with a return of radiotherapy-related toxicity to grade 1 or less (CTCAE5.0); 9.ECOG score 0-2; 10. Expected survival time >3 months; 11. Adequate organ function, study participants had to meet the following laboratory measures: absolute neutrophil count (ANC) ≥1.5x109/L without using granulocyte colony-stimulating factor for the past 14 days; platelet count ≥100×109/L without blood transfusion in the past 14 days; hemoglobin >9g/dL in the absence of blood transfusion or erythropoietin use in the past 14 days; Total bilirubin ≤1.5 times upper limit of normal value (ULN) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 ×ULN (participants with liver metastases were allowed ALT or AST ≤5×ULN); serum creatinine ≤1.5 times ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min; good coagulation function, defined as INR or PT ≤1.5 times ULN; Euthyroid, defined as thyroid stimulating hormone (TSH) within the normal range. If the baseline TSH level was outside the normal range, participants were eligible if their total T3 (or FT3) and FT4 levels were within the normal range. Myocardial enzymes within the normal range (isolated laboratory abnormalities that were judged by the investigators as not clinically significant were also allowed). Study participants were discretionary in applying the study regimen.排除标准:Exclusion Criteria:
Malignant diseases other than NSCLC diagnosed within 5 years before the first dose (excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, and/or radical resection in situ carcinoma); Are currently participating in an interventional clinical study treatment, or have received another study drug or study device within 4 weeks before the first dose; Prior therapy with: Anti-pd-1, anti-PD-L1 agents or agents targeting another T-cell receptor that stimulates or coinhibits it (e.g., CTLA-4, OX-40, CD137) Such as tislelizumab, toripalimab, carrelizumab, atezolizumab, slulizumab, pembrolizumab, paiampalimab, nivolumab, duvalumab, ipilimumab, etc. Received systemic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon and interleukin, except for local use to control pleural effusion) with indications for anti-NSCLC within 2 weeks before the first dose; Active autoimmune disease requiring systemic therapy (e.g., disease-modifying agents, glucocorticoids, or immunosuppressive agents) occurred within 2 years before the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) were not considered systemic therapy; Presence of clinically uncontrollable pleural/peritoneal effusion (participants who did not require fluid drainage or who stopped drainage for 3 days without a significant increase in fluid volume were eligible); Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation; Patients with known allergy to sintilimab, pemetrexed, gemcitabine, carboplatin, cisplatin and other active ingredients or excipients of the study drug; Has not fully recovered from any intervention-related toxicity and/or complications before starting treatment (i.e., grade ≤1 or baseline, excluding fatigue or alopecia); Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive); Untreated active hepatitis B (defined as both HBsAg positivity and HBV-DNA copies greater than the upper limit of normal in the laboratory at the participating center); HBV viral load <1000 copies /ml (200 IU/ml) before the first dose, study participants should receive anti-HBV therapy throughout the study chemotherapy to avoid viral reactivation Study participants with anti-HBc (+), HBsAg (-), anti-hbs (-), and HBV viral load (-) do not require prophylactic anti-HBV therapy, but close monitoring for viral reactivation is required 12. Active HCV-infected study participants with positive HCV antibodies and HCV-RNA levels above the lower limit of detection; 13. A live vaccine dose within 30 days before the first dose (cycle 1, day 1); Note: Administration of injectable inactivated virus vaccine against seasonal influenza within 30 days before the first dose is allowed; Live, attenuated, intranasal influenza vaccine was not allowed. The presence of any serious or uncontrolled systemic illness, such as: significant rhythm, conduction or morphological abnormalities in resting ECG, such as complete left bundle branch block, ≥ Ⅱ degree heart block, ventricular arrhythmia or atrial fibrillation; unstable angina, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure; myocardial infarction within 6 months before enrollment; poor blood pressure control (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); patients had a history of noninfectious pneumonia requiring glucocorticoid treatment within 1 year before the first dose of glucocorticoid, or current clinically active interstitial lung disease; active pulmonary tuberculosis; presence of active or uncontrolled infection requiring systemic therapy; presence of clinically active diverticulitis, abdominal abscess, or gastrointestinal obstruction; liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; poorly controlled diabetes (fasting blood glucose (FBG) > 10mmol/L); Urine routine test showed urinary protein ≥++ and confirmed 24-hour urinary protein quantitation > 1.0 g; participants with a psychiatric disorder who were unable to cooperate with treatment; Any medical history or evidence of illness, abnormal treatment or laboratory values, or other conditions that might interfere with the results of the trial or prevent full participation in the study were considered by the investigators to be other potential risks that might preclude participation.
引自 ClinicalTrials.gov, NCT06883136, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06883136,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。